Brian Powl Sells 4,345 Shares of Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Brian Powl sold 4,345 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $11.89, for a total value of $51,662.05. Following the completion of the sale, the insider owned 169,269 shares in the company, valued at approximately $2,012,608.41. The trade was a 2.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kura Oncology Stock Up 9.6%

Shares of NASDAQ KURA opened at $13.59 on Wednesday. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.73 and a quick ratio of 4.71. The stock has a market capitalization of $1.21 billion, a PE ratio of -4.03 and a beta of 0.38. Kura Oncology, Inc. has a one year low of $7.36 and a one year high of $13.90. The business’s fifty day moving average price is $10.67 and its 200-day moving average price is $9.54.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.The company had revenue of $20.87 million during the quarter, compared to analyst estimates of $20.16 million. On average, equities research analysts anticipate that Kura Oncology, Inc. will post -3.23 EPS for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on KURA. Citizens Jmp restated a “market outperform” rating and set a $24.00 target price on shares of Kura Oncology in a research report on Monday. Raymond James Financial set a $24.00 price objective on Kura Oncology in a research note on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a report on Friday, July 17th. CLSA set a $24.00 target price on Kura Oncology in a research note on Thursday, June 4th. Finally, Morgan Stanley set a $24.00 price target on Kura Oncology in a research report on Monday. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $25.40.

Kura Oncology News Summary

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: CEO makes sizable purchase: Chief Executive Officer Troy Edward Wilson bought 100,000 shares for approximately $1.24 million at an average price of $12.39. The purchase increased his direct stake by 26.37%, a potentially confidence-building signal for investors. SEC insider purchase filing
• Positive Sentiment: Analyst remains bullish: Citizens JMP reaffirmed a “Market Outperform” rating and set a $24 price target. That target implies substantial upside from the referenced trading level. Overall, analysts tracked in the report assign KURA a “Moderate Buy” consensus rating with an average target of $25.40. Benzinga analyst rating report
• Positive Sentiment: Institutional accumulation: California State Teachers’ Retirement System increased its position by 968% during the second quarter, while several other institutions initiated or expanded holdings. This may be supporting investor sentiment toward the clinical-stage oncology company.
• Neutral Sentiment: Short-interest data is inconclusive: The report lists short interest at zero shares on both August 10 and August 25, alongside an invalid “NaN” change. Consequently, it does not provide a reliable signal about short-covering or bearish positioning.
• Negative Sentiment: Insider sale disclosed: Insider Brian Powl sold 4,345 shares for approximately $51,662 at an average price of $11.89, reducing his holdings by 2.5%. The sale is relatively small compared with the CEO’s purchase but could temper the positive insider-trading signal. KURA insider sale report

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in KURA. IFP Advisors Inc boosted its stake in Kura Oncology by 115.3% during the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after buying an additional 1,284 shares during the period. Allworth Financial LP increased its stake in Kura Oncology by 59.9% in the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after acquiring an additional 1,553 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Kura Oncology by 49.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company’s stock valued at $60,000 after acquiring an additional 1,888 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Kura Oncology by 471.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after acquiring an additional 9,958 shares in the last quarter. Finally, Brevan Howard Capital Management LP bought a new stake in shares of Kura Oncology during the 2nd quarter valued at about $80,000.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.